Latest Recruitment News

Dimerix’s blinded review of its pivotal ACTION3 Phase 3 trial confirms over 90% statistical power to detect DMX-200’s effect on proteinuria, reinforcing the study’s design and regulatory pathway.

Orthocell’s latest Remplir™ Real World Evidence study reveals an 89.7% treatment success rate across 78 nerve repair procedures, reinforcing its clinical strength and fueling US and European market growth plans.

LTR Pharma has wrapped up recruitment for its SPONTAN Phase II pharmacokinetic study, with interim results expected soon to bolster FDA approval efforts. Meanwhile, US commercial talks for ROXUS advance cautiously under the FDA 503(a) personalised medicine pathway.

Cleo Diagnostics has kicked off a staged manufacturing program with Bio-Techne to produce ovarian cancer test kits, moving from clinical sample collection to analytical validation and FDA submission preparation.

Imricor Medical Systems advanced FDA clearances and expanded clinical trials in Q1 CY26, positioning for commercial growth despite higher operating cash outflows.

Platina Resources has launched an extensive 2026 drilling campaign across its Laverton gold portfolio, while advancing key acquisitions to nearly double its landholding and navigating leadership changes.

Paradigm Biopharmaceuticals has upsized a $14 million placement and launched a $2 million SPP, boosting its cash runway to around $45 million. This capital injection supports the ongoing Phase 3 trial for knee osteoarthritis, with interim results expected in Q3 2026.

MRG Metals’ joint venture partner Sinowin Lithium has delivered a comprehensive Environmental and Social Impact Assessment for the Corridor Central Titanium Dioxide project in Mozambique, marking a key regulatory milestone towards production in 2027.

CLINUVEL Pharmaceuticals has received final scientific advice from the European Medicines Agency on the design of its pivotal Phase III trial for SCENESSE in vitiligo, endorsing a comprehensive evidence approach and prioritising patients with darker skin tones.

PLS Group delivered a record 232.4kt spodumene concentrate production in March 2026, lifted revenue 52% to A$567 million on soaring lithium prices, and strengthened its balance sheet with a US$600 million senior notes issuance.

Cambium Bio has secured FDA confirmation that a single pivotal Phase 3 trial plus confirmatory evidence will suffice for Biologics License Application submission for Elate Ocular, significantly reducing development expenses and accelerating the pathway to market.

Cavalier Resources has secured a $4 million placement at an 11.95% discount to the 15-day VWAP, funding critical pre-production activities at its Crawford Gold Project. This capital injection complements ongoing negotiations for a US$13 million gold prepayment and a A$5 million loan, advancing the project toward production.